Heraeus Nexensos Supports Vaccine Cold-chain Logistics with Temperature Sensors: Company Is Increasing Production Capacity to Meet the Demand

Heraeus Nexensos advises providing a perfect cold chain for temperature-sensitive pharmaceutical products, such as vaccines and other biologicals, is a major logistical challenge for the pharmaceutical industry.  

Heraeus Nexensos platinum-based resistance temperature detectors (RTD) are a perfect fit for harsh cryogenic sensing applications. Heraeus RTD sensors provide reliable and accurate temperature measurement in dry ice (-78 °C), with capability down to -200 °C. Platinum RTDs exhibit extremely low drift, even after years of service, ensuring reliable data collection for the life of the measurement device. This reliability translates to precise monitoring of temperature-sensitive biochemical synthesis processes, and secure temperature control and monitoring for the complete cold chain logistic, from shipment to storage. 

“Heraeus sensors for cryogenic temperature measurement offer superior precision. More than 500 Million of delivered sensor elements have proven their reliability and outstanding performance in harsh environments. We are glad to support the efficacy and safety of cryo chains, especially for the logistics of vaccines against SARS-Cov-2.”, says Ralph Meschkat, President of Heraeus Nexensos. “We have already invested in 2020 in additional capacity and use this now to support increasing demand in this area. With our advanced planning system, we can now offer unmatched delivery times.” 

As the worldwide market and technology leader for platinum-based Resistance Temperature Sensors (RTD elements) Heraeus Nexensos offers its customers technical support in every major time zone in the world via application centers located in the US, China and Europe.  Sensor elements are available in tailormade sizes in support of various industrial applications. Nexensos’ production system and global inventories support short lead times and flexible supply arrangements.  

Platinum-based sensors are ideal for temperature measurement in challenging applications. The linear characteristics allow precise temperature sensing over the full measurement range. Applications include the monitoring of production process temperature stability, cryo-transport box temperature during transport, and ultra-low storage cooler temperature. Sensors are available for temperature measurement over a wide range from -200 to +1000 °C. Nexensos RTDs installed in harsh environments, such as automotive systems or power plants, exhibit a typical lifetime of 15 to 20 years.  

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”